The GBA drug connect: how Hong Kong-approved medicines reach Guangdong, and the catch
A real channel to get Hong Kong/Macao medicines and devices on the mainland, but it works hospital-by-hospital and drug-by-drug. Being approved in Hong Kong is not enough.
There is a genuine, legal way to be treated on the Chinese mainland with a drug or device that is approved in Hong Kong or Macao but not yet approved nationally in China. It is a Greater Bay Area (GBA) policy usually called the "drug and device connect" (港澳药械通). It is real and it works — but the way it works trips up almost everyone, so read the catch carefully.
What it is
Under a 2020 national policy — the Work Plan for Regulatory Innovation and Development of Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area — approval authority for certain clinically urgent, already-Hong-Kong/Macao-marketed drugs and devices was delegated from the national regulator down to the Guangdong provincial drug administration.
In plain terms: instead of waiting years for a drug to clear national China registration, a qualifying hospital in the Greater Bay Area can import and use a Hong Kong-marketed version now, under provincial approval.
The GBA here means the nine mainland cities of the region — Guangzhou, Shenzhen, Zhuhai, Foshan, Dongguan, Zhongshan, Huizhou, Jiangmen, Zhaoqing.
The catch (read this twice)
Being approved in Hong Kong does not make a drug available across Guangdong. Availability is a two-key lock, and both keys are needed:
- The hospital must be a designated institution (指定医疗机构). Only specific, named hospitals are authorized to run this channel. Most hospitals in Guangzhou or Shenzhen are not on the list.
- The specific drug or device must have been applied for and approved at that hospital. A designated hospital does not automatically stock every Hong Kong drug. Each product is brought in against a stated clinical need, often for a specific indication, sometimes tied to a specific physician's request.
So the real question is never "is this drug approved in Hong Kong?" It is "is there a designated hospital that has already brought in this specific drug, and will it take me as a patient?" That is a matrix of (hospital × product), not a simple yes/no.
And there is a third, human key: a hospital has to be willing. Bringing in a single overseas medicine for one foreign patient is administrative work with pharmacovigilance responsibility attached. Not every designated hospital will do it for a one-off international patient. This is the part marketing pages leave out.
How it started, how big it is now
The flagship was the University of Hong Kong-Shenzhen Hospital (香港大学深圳医院), the first designated institution when the channel opened around 2021. Since then the list of designated institutions has grown across all nine GBA cities, and the catalog of approved drugs and devices has expanded steadily.
Important limits
- Use is confined to the designated hospital. These products are used under that institution's supervision. This is not a take-home import scheme, and it is certainly not a route to buy and ship medicine — which this site never facilitates anyway.
- It is built for Bay Area access, not medical tourism. The policy's logic is regional healthcare integration. A foreign patient can potentially benefit, but only by being treated at a participating hospital for a product that hospital already runs.
- You pay for it. These are self-pay in practice for a foreign visitor.
How to actually use this channel
- Identify the exact drug or device you need (Hong Kong trade name and active ingredient).
- Find which designated GBA hospital has brought that product in. The authoritative list is maintained by the Guangdong drug administration; we are working to index it on this site.
- Contact that hospital's international department to confirm they will accept you and that the product is currently available for your indication.
- Have your diagnosis and records ready — access is tied to clinical need.
Boao Lecheng: the other door
If your drug is approved in the US/EU/Japan but nowhere in China (not Hong Kong either), the GBA connect will not help — its products must be Hong Kong/Macao-marketed. The channel for globally-approved-but-not-in-China drugs is a different policy in Hainan, the Boao Lecheng zone, covered in its own article.
Sources & verification status
- Policy basis: Work Plan for Regulatory Innovation and Development of Drugs and Medical Devices in the GBA (2020). Official title, issuing agencies, and date pending verification against the primary document; administered by the Guangdong Medical Products Administration.
- Designated-institution mechanism and the two-key (hospital × product) rule: reflects how the channel operates in practice; primary-source wording and the current designated-institution / approved-product lists are pending verification — we will replace the tagged figures with cited official numbers.
- University of Hong Kong-Shenzhen Hospital as first pilot (c. 2021)